Michael Anstead, Sonya L. Heltshe, Umer Khan, Joseph T

Slides:

Advertisements

Similar presentations

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

Advertisements

Cheryl Cameron, Mark W. Lodes, William M. Gershan

Christopher C. Miller, Christopher A

Serology as a diagnostic tool for predicting initialPseudomonas aeruginosa acquisition in childrenwith cystic fibrosis Cori Daines, Donald VanDeVanter,

Is infection with hypermutable Pseudomonas aeruginosa clinically significant? Adi Auerbach, Eitan Kerem, Marc Victor Assous, Elie Picard, Maskit Bar-Meir

Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort Margaret Rosenfeld, Julia Emerson, Sharon McNamara,

Early rise of anti-Pseudomonas antibodies and a mucoid phenotype of Pseudomonas aeruginosa are risk factors for development of chronic lung infection—A.

A. Mirakhur, M.J. Gallagher, M.J. Ledson, C.A. Hart, M.J. Walshaw

Complications of long and intermediate term venous catheters in cystic fibrosis patients: A multicenter study Teresa L. May, Alex H. Gifford, Thomas.

Scott D. Sagel, Marci K. Sontag, Meg M

Development of a quantitative immunofluorescence assay for detection of Stenotrophomonas maltophilia antibodies in patients with cystic fibrosis P. Gonçalves.

A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children.

Patrick A. Flume, John P. Clancy, George Z. Retsch-Bogart, D

Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis M. Proesmans, F. Vermeulen,

Samantha A. Woodruff, Marci K. Sontag, Frank J. Accurso, Ronald J

Urinary incontinence in 9��16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group W.J. Browne, C.J. Wood, M.

Regional ventilation in cystic fibrosis measured by electrical impedance tomography Zhanqi Zhao, Rainald Fischer, Inéz Frerichs, Ullrich Müller-Lisse,

Early attained weight and length predict growth faltering better than velocity measures in infants with CF Sonya L. Heltshe, Drucy S. Borowitz, Daniel.

Frank J. Accurso, Fredrick Van Goor, Jiuhong Zha, Anne J

A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study Maret L. Maliniak, Arlene A.

Cirrhosis and other liver disease in cystic fibrosis

A pilot study on the safety and efficacy of a novel antioxidant rich formulation in patients with cystic fibrosis Konstantinos A. Papas, Marci K. Sontag,

Amanda L. Brennan, Khin M. Gyi, David M

Pulmonary exacerbations in CF patients with early lung disease

Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study Christine Rønne.

Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox

Comparison of real time diagnostic chemistries to detect Pseudomonas aeruginosa in respiratory samples from cystic fibrosis patients J.L. Fothergill,

Laboratory parameter profiles among patients with cystic fibrosis

Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn

Implementation of European standards of care for cystic fibrosis �� Control and treatment of infection J.S. Elborn, M. Hodson, C. Bertram Journal of.

The Journal of Cystic Fibrosis: Sunny perspectives

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation.

A.H. Gifford Journal of Cystic Fibrosis

Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009 Yolanda P. Lillquist,

Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis Sanja Stanojevic, Valerie Waters, Joseph L.

Tregony Simoneau, Gregory S. Sawicki, Carly E. Milliren, Henry A

Antonia V. Bennett, Donald L. Patrick, James F. Lymp, Todd C

Maximal daily dose of pancreatic enzyme replacement therapy in infants with cystic fibrosis: A reconsideration Drucy Borowitz, Daniel Gelfond, Karen.

Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis D.W. Reid, R. Latham, I.L.

Prevalence and risk factors for recovery of filamentous fungi in individuals with cystic fibrosis Christopher R. Sudfeld, Elliott C. Dasenbrook, William.

Inflammatory and immunological biomarkers are not related to survival in adults with Cystic Fibrosis K.L. Moffitt, S.L. Martin, A.M. Jones, A.K. Webb,

Design and powering of cystic fibrosis clinical trials using rate of FEV1 decline as an efficacy endpoint M.W. Konstan, J.S. Wagener, A. Yegin, S.J.

Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled.

Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients Valerie Waters, Eshetu G. Atenafu, Annie.

Segregation of children with CF diagnosed via newborn screening and acquisition of Pseudomonas aeruginosa Karen O. McKay, Peter J. Cooper, Peter P. van.

Predictive values of antibodies against Pseudomonas aeruginosa in patients with cystic fibrosis one year after early eradication treatment Matthias Kappler,

Higher risk of hospitalization among females with cystic fibrosis

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

V. Thompson, N. Mayer-Hamblett, M. Kloster, D. Bilton, P.A. Flume

Serology as a diagnostic tool for predicting initialPseudomonas aeruginosa acquisition in childrenwith cystic fibrosis Cori Daines, Donald VanDeVanter,

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

James H. Hull, Rachel Garrod, Timothy B. Ho, Ronald K. Knight, John R

The impact of switching to the new global lung function initiative equations on spirometry results in the UK CF Registry Sanja Stanojevic, Janet Stocks,

Impact of IVS8-(TG)m(T)n on IRT and sweat chloride levels in newborns identified by California CF newborn screening Steven Keiles, Ruth Koepke, Richard.

Michael W. Konstan, David J. Pasta, Jeffrey S. Wagener, Donald R

Serum-surfactant SP-D correlates inversely to lung function in cystic fibrosis Hanne Vebert Olesen, Uffe Holmskov, Peter Oluf Schiøtz, Grith Lykke Sørensen

Bedside prediction of the central venous catheter insertion depth

Cheryl Cameron, Mark W. Lodes, William M. Gershan

Brian S. Murphy, Heather M

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)—A cause for concern?

Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa C.E. Wainwright, A.L. Quittner, D.E.

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

B. Martha, D. Croisier, A. Fanton, K. Astruc, L. Piroth, F. Huet, P

Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations, 1995–2005 Donald R. VanDevanter, Eric P. Elkin,

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial Michael W. Konstan, Patrick A. Flume, Matthias.

Improved early diagnosis of Pseudomonas aeruginosa by real-time PCR to prevent chronic colonisation in a paediatric cystic fibrosis population Elaine.

Safety assessment of inhaled xylitol in subjects with cystic fibrosis

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience C.R.

Presentation transcript:

Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial Michael Anstead, Sonya L. Heltshe, Umer Khan, Joseph T. Barbieri, Markus Langkamp, Gerd Döring, Shimoni Dharia, Ronald L. Gibson, Miriam M. Treggiari, James Lymp, Margaret Rosenfeld, Bonnie Ramsey Journal of Cystic Fibrosis Volume 12, Issue 2, Pages 147-153 (March 2013) DOI: 10.1016/j.jcf.2012.08.001 Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

Fig. 1 Distribution of individual antigen titers by concurrent culture status for all 975 serum samples. Pa+ indicates P. aeruginosa positive, Pa− indicates P. aeruginosa negative. Hash lines are the median values, boxes represent the 25th and 75th percentiles (inter-quartile range), whiskers extend to minimum and maximum or 1.5× the inter-quartile range (whichever is smaller), outliers are marked as circles. Journal of Cystic Fibrosis 2013 12, 147-153DOI: (10.1016/j.jcf.2012.08.001) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

Fig. 2 Culture positivity and seropositivity over time. The solid black line shows the proportion culture positive for P. aeruginosa across each visit among the 303 subjects with available serology. The dashed lines show the proportion of samples seropositive at each visit for each combined ELISA. A combined ELISA is defined as seropositive if any one of the three antigens in an ELISA has titer at least 100. Journal of Cystic Fibrosis 2013 12, 147-153DOI: (10.1016/j.jcf.2012.08.001) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

Fig. 3 Baseline serology titers by respiratory culture status using modified Leeds criteria. Subjects were classified as ‘Pa free’ if they were clear of P. aeruginosa from baseline through end of study, ‘Intermittent’ if they had less than half of all available cultures testing positive for P. aeruginosa, and ‘Chronic’ if they had half or more of all available cultures testing positive for P. aeruginosa. Hash lines are the median values, boxes represent the 25th and 75th percentiles (inter-quartile range), whiskers extend to minimum and maximum or 1.5× the inter-quartile range (whichever is smaller), outliers are marked as circles. Journal of Cystic Fibrosis 2013 12, 147-153DOI: (10.1016/j.jcf.2012.08.001) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions